Search
mosunetuzumab-axgb (Lunsumio)
Indications:
- refractory follicular lymphoma
Contraindications:
- pregnancy
Dosage:
- administer 8 cycles
- unless complete response, an additional 9 cycles of treatment (17 cycles total)
- premedicate to reduce risk of cytokine release syndrome & infusion-related reaction
- cycle 1 day 1: 1 mg
- cycle 1 day 8: 2 mg
- cycle 1 day 15: 60 mg
- cycle 2 day 1: 60 mg
- cycle 3+ day 1: 30 mg
* a treatment cycle is 21 days
* cycle 1: administer over minimum of 4 hours
* subsequent cycles: administer over minimum of 2 hours if cycle 1 well tolerated
* premedicate with dexamethasone 20 mg or methylprednisolone 80 mg IV, diphenhydramine 50-100 mg, acetaminophen 500-1000 mg 30 minutes prior to infusion (all patients cycles 1 & 2), & subsequent cycles for patients who experienced cytokine release syndrome during cycles 1 & 2.
1 mg/mL: 1 mL, 30 mL
Adverse effects:
- common (>= 20%)
- cytokine release synndrome
- fatigue, rash, pyrexia, headache
- laboratory abnormalities (>= 10%)
- lymphopenia, leukopenia, neutropenia, anemia, thrombocytopenia
- hypoglycemia, hypophosphatemia, increased serum uric acid
- tumor flare
- Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
- fetal-embryo toxicity
Mechanism of action:
- bispecific CD20-directed CD3 T-cell engager
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
antineoplastic monoclonal antibody
References
- Food and Drug Administration (FDA) December 22, 2022
FDA grants accelerated approval to mosunetuzumab-axgb for relapsed or refractory
follicular lymphoma.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-mosunetuzumab-axgb-relapsed-or-refractory-follicular-lymphoma
- HIGHLIGHTS OF PRESCRIBING INFORMATIO
Lunsumio (mosunetuzumab-axgb) injection, for intravenous
https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761263s000lbl.pdf